Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Over the last 12 months, insiders at Medtronic plc have bought $0 and sold $6.38M worth of Medtronic plc stock.
On average, over the past 5 years, insiders at Medtronic plc have bought $1.55M and sold $23.37M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,010 shares for transaction amount of $517,333 was made by ANDERSON RICHARD H (director) on 2021‑12‑16.
2024-06-07 | Sale | Martha Geoffrey | Chairman and CEO | 19,113 0.0015% | $83.77 | $1.6M | -3.60% | |
2024-04-08 | Sale | Marinaro Michael | EVP & President, Surgical OU | 854 <0.0001% | $83.14 | $71,002 | -1.56% | |
2024-02-21 | Sale | Salmon Sean | EVP & President Cardiovascular | 30,695 0.0023% | $85.13 | $2.61M | -3.36% | |
2023-12-19 | Sale | Wall Brett A. | EVP & Pres Neuroscience | 4,997 0.0004% | $82.17 | $410,603 | +1.97% | |
2023-08-23 | Sale | Smith Gregory L | EVP Global Ops & Supply Chain | 10,000 0.0008% | $83.84 | $838,400 | -2.06% | |
2023-08-14 | Sale | Wall Brett A. | EVP & Pres Neuroscience | 1,000 <0.0001% | $83.38 | $83,380 | -1.46% | |
2023-08-04 | Sale | Marinaro Michael | EVP & President, Surgical OU | 1,352 0.0001% | $84.11 | $113,717 | -2.42% | |
2023-07-14 | Sale | Wall Brett A. | EVP & Pres Neuroscience | 2,000 0.0002% | $87.97 | $175,940 | -6.20% | |
2023-07-10 | Sale | TEN HOEDT ROB | EVP and Pres. Global Regions | 5,514 0.0004% | $86.58 | $477,420 | -4.87% | |
2022-12-13 | Sale | Salmon Sean | EVP & President Cardiovascular | 16,631 0.0013% | $80.50 | $1.34M | +3.72% | |
2022-10-14 | Sale | TEN HOEDT ROB | EVP and Pres. Global Regions | 2,404 0.0002% | $81.54 | $196,015 | +2.51% | |
2022-03-18 | Sale | PARKHILL KAREN L | EVP & Chief Financial Officer | 682 <0.0001% | $110.00 | $75,020 | -19.30% | |
2022-03-11 | Sale | Surface Carol A | SVP, Chief HR Officer | 6,000 0.0005% | $105.30 | $631,800 | -14.10% | |
2021-12-23 | Sale | WHITE ROBERT JOHN | EVP & Pres. Medical Surgical | 7,218 0.0005% | $102.04 | $736,525 | -8.14% | |
2021-12-16 | ANDERSON RICHARD H | director | 5,010 0.0004% | $103.26 | $517,333 | -6.07% | ||
2021-12-06 | Sale | PARKHILL KAREN L | EVP & Chief Financial Officer | 682 <0.0001% | $110.00 | $75,020 | -11.83% | |
2021-09-30 | Sale | Lerman Bradley E | SVP General Counsel & Corp Sec | 49,147 0.0037% | $126.58 | $6.22M | -16.50% | |
2021-08-31 | Sale | Lerman Bradley E | SVP General Counsel & Corp Sec | 50,775 0.0038% | $134.17 | $6.81M | -20.23% | |
2021-08-25 | Sale | Martha Geoffrey | CEO | 10,100 0.0007% | $132.67 | $1.34M | -20.38% | |
2021-08-25 | Sale | Salmon Sean | EVP & Pres Diabetes/Cardiovasc | 28,419 0.0021% | $134.08 | $3.81M | -20.38% |
Martha Geoffrey | CEO | 143348 0.0072% | $80.05 | 0 | 7 | |
Smith Gregory L | EVP Global Ops & Supply Chain | 46723 0.0035% | $80.05 | 0 | 1 | |
TEN HOEDT ROB | EVP and Pres. Global Regions | 43802 0.0033% | $80.05 | 0 | 9 | |
Salmon Sean | EVP & President Cardiovascular | 48289 0.0027% | $80.05 | 0 | 3 | |
Wall Brett A. | EVP & Pres Neuroscience | 28910 0.0022% | $80.05 | 0 | 5 | |
Marinaro Michael | EVP & President, Surgical OU | 27925 0.0022% | $80.05 | 0 | 2 | |
ISHRAK OMAR | Executive Chairman | 561032 0.0422% | $80.05 | 2 | 7 | +5.04% |
COYLE MICHAEL J | EVP & Group Pres, Cardiac&Vasc | 188262 0.0142% | $80.05 | 0 | 4 | |
Ellis Gary Lee | EVP & Global Ops and IT | 180939 0.0136% | $80.05 | 0 | 2 | |
ANDERSON RICHARD H | director | 108374 0.0082% | $80.05 | 6 | 0 | +0.88% |
OConnell Christopher J | EVP & GroupPres Restora Therap | 93274 0.007% | $80.05 | 0 | 2 | |
Hanson Bryan C | EVP, President, MITG | 88818 0.0067% | $80.05 | 0 | 10 | |
Kuntz Richard | SVP & Chief Medical & Science | 71013 0.0053% | $80.05 | 0 | 13 | |
POZEN ROBERT C | director | 60964 0.0046% | $80.05 | 1 | 1 | +11.75% |
Lerman Bradley E | SVP General Counsel & Corp Sec | 48763 0.0037% | $80.05 | 0 | 9 | |
Lenehan James T | director | 47028 0.0035% | $80.05 | 1 | 1 | +7.69% |
Liddicoat John R | EVP & President of Americas | 42551 0.0032% | $80.05 | 0 | 1 | |
OLEARY DENISE M | director | 40607 0.0031% | $80.05 | 0 | 1 | |
WHITE ROBERT JOHN | EVP & Pres. Medical Surgical | 39430 0.003% | $80.05 | 0 | 4 | |
PARKHILL KAREN L | EVP & Chief Financial Officer | 34946 0.0026% | $80.05 | 1 | 6 | +19.19% |
JACKSON SHIRLEY A | director | 33989 0.0026% | $80.05 | 0 | 2 | |
HAKAMI HOOMAN | EVP & Group President Diabetes | 30761 0.0023% | $80.05 | 0 | 5 | |
Surface Carol A | SVP, Chief HR Officer | 28502 0.0021% | $80.05 | 0 | 8 | |
Powell Kendall J | director | 26375 0.002% | $80.05 | 0 | 1 |
The Vanguard Group | $11.01B | 9.63 | 126.28M | -0.21% | -$23.07M | 0.21 | |
BlackRock | $9.93B | 8.69 | 113.98M | -3.87% | -$400.24M | 0.23 | |
State Street | $5.28B | 4.58 | 60.07M | -1.39% | -$74.31M | 0.23 | |
JPMorgan Chase | $2.76B | 2.41 | 31.63M | +24.59% | +$543.97M | 0.25 | |
Capital Research Global Investors | $2.69B | 2.36 | 30.88M | +7.09% | +$178.14M | 0.61 | |
Morgan Stanley | $2.35B | 2.06 | 27M | +15.98% | +$324.29M | 0.18 | |
Geode Capital Management | $2.32B | 2.03 | 26.65M | -0.3% | -$7M | 0.21 | |
Massachusetts Financial Services Co Ma | $2.22B | 1.94 | 25.49M | -11.75% | -$295.86M | 0.66 | |
Wellington Management Company | $2.04B | 1.79 | 23.42M | -2.46% | -$51.58M | 0.35 | |
Bank of America | $2.01B | 1.76 | 23.06M | +2.21% | +$43.52M | 0.2 | |
BNY Mellon | $1.9B | 1.66 | 21.82M | +3.45% | +$63.44M | 0.36 | |
Franklin Templeton Investments | $1.69B | 1.48 | 19.43M | +0.37% | +$6.24M | 0.51 | |
Deutsche Bank | $1.48B | 1.3 | 17.03M | -1.71% | -$25.85M | 0.68 | |
T. Rowe Price | $1.3B | 1.14 | 14.92M | -3.14% | -$42.11M | 0.16 | |
Royal Bank of Canada | $1.12B | 0.98 | 12.9M | +2.13% | +$23.51M | 0.27 | |
Sanders Capital Llc | $1.11B | 0.97 | 12.71M | +0.57% | +$6.31M | 1.85 | |
Northern Trust | $1.06B | 0.93 | 12.18M | -4.37% | -$48.46M | 0.18 | |
Legal & General | $1.02B | 0.89 | 11.69M | -0.87% | -$8.94M | 0.24 | |
American Century Investments | $981.82M | 0.86 | 11.27M | +0.5% | +$4.88M | 0.6 | |
Ameriprise Financial | $977.03M | 0.86 | 11.21M | +0.97% | +$9.42M | 0.27 | |
Charles Schwab | $953.52M | 0.86 | 11.22M | +1.16% | +$10.92M | 0.22 | |
AllianceBernstein | $964.58M | 0.84 | 11.07M | +5.44% | +$49.78M | 0.34 | |
Invesco | $892.47M | 0.78 | 10.24M | -11.79% | -$119.32M | 0.19 | |
First Eagle Investment Management | $820.53M | 0.72 | 9.42M | +0.06% | +$477,233.42 | 1.87 | |
Aristotle | $744.04M | 0.65 | 8.54M | -0.75% | -$5.63M | 1.43 | |
Wells Fargo | $688.18M | 0.6 | 7.9M | -39.5% | -$449.3M | 0.18 | |
Voya Investment Management | $668.37M | 0.59 | 7.67M | +2.25% | +$14.7M | 2.3 | |
Hotchkis & Wiley Capital Management | $631.17M | 0.55 | 7.24M | +16.12% | +$87.61M | 2.13 | |
Goldman Sachs | $605.22M | 0.53 | 6.94M | +15.68% | +$82.04M | 0.12 | |
Dodge & Cox | $591.69M | 0.52 | 6.79M | +0.14% | +$823,567.50 | 0.34 | |
Longview Partners (Guernsey) LTD | $578.24M | 0.51 | 6.64M | +2.28% | +$12.88M | 3.73 | |
Dimensional Fund Advisors | $575.61M | 0.5 | 6.6M | +0.88% | +$5.01M | 0.16 | |
Ubs Asset Management Americas Inc | $545.31M | 0.48 | 6.26M | +1.15% | +$6.21M | 0.19 | |
Barrow Hanley Global Investors | $542.73M | 0.48 | 6.23M | -3.2% | -$17.97M | 1.86 | |
Raymond James Associates | $515.03M | 0.45 | 5.91M | -0.22% | -$1.14M | 0.35 | |
Stifel | $488.74M | 0.43 | 5.61M | +4.67% | +$21.8M | 0.57 | |
Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $483.17M | 0.42 | 5.54M | +133.66% | +$276.39M | 0.55 | |
LAZARD ASSET MANAGEMENT LLC | $460.8M | 0.4 | 5.29M | -8.88% | -$44.91M | 0.61 | |
Fisher Asset Management Llc | $429.51M | 0.38 | 4.93M | +7.32% | +$29.28M | 0.2 | |
Nuveen | $426.46M | 0.37 | 4.89M | -4.03% | -$17.89M | 0.13 | |
Arrowstreet Capital, Limited Partnership | $422.04M | 0.37 | 4.84M | +8.16% | +$31.82M | 0.39 | |
VanEck | $398.44M | 0.35 | 4.57M | +10.45% | +$37.69M | 0.61 | |
Envestnet Asset Management Inc | $384.18M | 0.34 | 4.41M | -0.33% | -$1.28M | 0.15 | |
Amundi | $325.01M | 0.31 | 4.1M | -20.72% | -$84.94M | 0.14 | |
UBS | $356.91M | 0.31 | 4.1M | +9.06% | +$29.64M | 0.11 | |
Swiss National Bank | $347.02M | 0.3 | 3.98M | -4.29% | -$15.57M | 0.24 | |
Diamond Hill Investment Group Inc | $344.1M | 0.3 | 3.95M | +1.23% | +$4.19M | 1.41 | |
1832 Asset Management LP | $337.6M | 0.3 | 3.87M | +26.86% | +$71.48M | 0.62 | |
Barclays | $324.72M | 0.28 | 3.73M | +6.03% | +$18.45M | 0.15 | |
State Farm | $315.67M | 0.28 | 3.62M | 0% | +$0 | 0.28 |